Close
Manto Gudzinevičiaus nuotr.
For them, this opening represents more than new walls and equipment. It’s a symbol of how far they’ve come, the challenges they’ve overcome, and the values that continue to guide them: perseverance, ownership, and innovation.
Where it all began
Atrandi’s roots stretch back to pioneering work in droplet microfluidics. Led by Prof. Linas Mažutis, the team was among the first to explore how droplets could transform single-cell biology.
“Back then, we were thinking about how to make droplet microfluidics technology applicable to a broader range of applications. Through a series of innovations, Atrandi has created a novel technology that not only improves nucleic acid analysis but also paves the way for many exciting applications in single-cell biology research,” says Prof. Linas Mažutis, co-founder.
Science that opens new horizons
From droplets, Atrandi took a bold step forward. The team created Semi-Permeable Capsules (SPCs) – a new class of technology that doesn’t just isolate cells, but enables complex, multi-step workflows at single-cell resolution. With SPCs, true multiomics becomes possible.
“Innovation means never settling. For us, SPCs technology is not just an incremental step – it's a foundation for the next generation of tools and applications. We believe this technology will impact life sciences globally,” says Juozas Nainys, CEO and co-founder.
SPCs are already proving their value across diverse applications – from microbial dark matter to cancer genomics. For scientists, the ability to run sequential reactions on the same cell opens up questions that were once impossible to ask.
“Science advances when we can ask what we couldn’t before. SPCs allow us to connect genotypes to phenotypes, link microbes to their viruses, and map complexity in ways that bulk methods could never resolve,” explains Rapolas Žilionis, CSO and co-founder.
Engineering the impossible
Behind every breakthrough is the craft of making technology work in practice.
“Our challenge has always been to turn a beautiful scientific idea into a reliable tool in scientists’ hands. SPCs demanded us to rethink rethink microfluidics and its material engineering from the ground up – and that’s exactly what we did,” notes Dalius Kučiauskas, Director of Engineering and co-founder.
The shift from droplets to capsules has positioned Atrandi at the forefront of single-cell multiomics.
“Droplets were the first revolution – and we were proud to be part of that. But SPCs open a completely new space for biology. This is not the end of one chapter, it’s the beginning of many more,” says Karolis Leonavičius, CTO and co-founder.
A global story of science and perseverance
For Atrandi, this new office is not just about physical space – it’s about creating an environment where bold ideas can grow into technologies that shape the future of life sciences.
Their mission is simple: to give scientists the tools they need to unlock biology at single-cell resolution.
“Atrandi values keep us grounded: ownership drives discovery, perseverance pushes us through challenges, and innovation reminds us we are part of something bigger – a worldwide movement advancing single-cell biology.
We are grateful to our partners, investors, and collaborators across the global biotech ecosystem. Without your trust and support, this journey would not be possible. This new office is not an endpoint. It’s a launchpad – for ideas, for collaborations, and for the next era of single-cell multiomics.“ says Atrandi.
